Earnings Releases·Oct 28, 2026, 7:05 AM ET

Replimune — Fiscal Second Quarter 2027 Earnings Summary

Net loss narrowed to $57.1 million from $83.1 million year-over-year, with R&D and SG&A expenses declining to $34.4 million and $21.9 million respectively.
Cash and cash equivalents increased to $307.8 million, driven by $141.0 million in equity proceeds and a $15.0 million debt drawdown, extending runway to over twelve months.
TUDRIQEV commercialization is advancing with over 15 institutions prescribing the therapy, 70% of priority accounts engaged, and listing in NCCN guidelines as a category 2A recommendation.
Confirmatory IGNYTE-3 Phase 3 trial and REVEAL Phase 2/3 registration trial are actively enrolling, with accelerated approval contingent on verifying clinical benefit.
No changes to financial guidance were issued; management remains focused on commercial adoption and manufacturing goals despite risks related to adverse reactions and regulatory verification.